https://www.artismediclimited.com Tue, 03 May 2022 13:05:58 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 214938821 https://www.artismediclimited.com/2022/04/28/helsinn-launches-fully-integrated-targeted-therapy-fitt-strategy-and-announces-leadership-and-structural-changes/ https://www.artismediclimited.com/2022/04/28/helsinn-launches-fully-integrated-targeted-therapy-fitt-strategy-and-announces-leadership-and-structural-changes/#respond Thu, 28 Apr 2022 04:32:57 +0000 https://www.artismediclimited.com/?p=39 Lugano, Switzerland, January 13, 2022 – Helsinn Group (“AMPL”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces the launch of its Fully Integrated Targeted Therapy (FITT) Strategy and Board and management changes

]]> https://www.artismediclimited.com/2022/04/28/helsinn-launches-fully-integrated-targeted-therapy-fitt-strategy-and-announces-leadership-and-structural-changes/feed/ 0 39 https://www.artismediclimited.com/2022/04/28/anacardio-exercises-option-to-license-a-program-in-heart-failure-from-helsinn%ef%bf%bc/ https://www.artismediclimited.com/2022/04/28/anacardio-exercises-option-to-license-a-program-in-heart-failure-from-helsinn%ef%bf%bc/#respond Thu, 28 Apr 2022 04:32:15 +0000 https://www.artismediclimited.com/?p=37 Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“AMPL”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has exercised its option to license from AMPL a program in heart failure, a condition which is associated with poor quality of life, poor prognosis and which remains a major unmet medical need.

]]> https://www.artismediclimited.com/2022/04/28/anacardio-exercises-option-to-license-a-program-in-heart-failure-from-helsinn%ef%bf%bc/feed/ 0 37 https://www.artismediclimited.com/2022/04/28/verity-pharmaceuticals-and-helsinn-therapeutics-sign-exclusive-agreement-for-the-promotion-of-akynzeo-and-valchlor-in-puerto-rico%ef%bf%bc/ https://www.artismediclimited.com/2022/04/28/verity-pharmaceuticals-and-helsinn-therapeutics-sign-exclusive-agreement-for-the-promotion-of-akynzeo-and-valchlor-in-puerto-rico%ef%bf%bc/#respond Thu, 28 Apr 2022 04:31:36 +0000 https://www.artismediclimited.com/?p=35 Verity Pharmaceuticals International Ltd. (“Verity Pharma”), and AMPL Therapeutics (U.S.), Inc. (“AMPL”), today announced the signing of an agreement between the two parties for the exclusive rights to promote AKYNZEO^® IV/Oral and VALCHLOR^® in Puerto Rico.

]]> https://www.artismediclimited.com/2022/04/28/verity-pharmaceuticals-and-helsinn-therapeutics-sign-exclusive-agreement-for-the-promotion-of-akynzeo-and-valchlor-in-puerto-rico%ef%bf%bc/feed/ 0 35 https://www.artismediclimited.com/2022/04/28/helsinn-group-and-bridgebio-pharma-announce-update-to-strategic-collaboration-to-develop-manufacture-and-commercialize-infigratinib-in-oncology-indications-in-the-u-s-%ef%bf%bc/ https://www.artismediclimited.com/2022/04/28/helsinn-group-and-bridgebio-pharma-announce-update-to-strategic-collaboration-to-develop-manufacture-and-commercialize-infigratinib-in-oncology-indications-in-the-u-s-%ef%bf%bc/#respond Thu, 28 Apr 2022 04:31:06 +0000 https://www.artismediclimited.com/?p=33 Lugano, Switzerland and Palo Alto, CA, March 3, 2022 – AMPL Group (AMPL), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced an update to their existing strategic collaboration to develop, manufacture and commercialize infigratinib for oncology indications.

]]> https://www.artismediclimited.com/2022/04/28/helsinn-group-and-bridgebio-pharma-announce-update-to-strategic-collaboration-to-develop-manufacture-and-commercialize-infigratinib-in-oncology-indications-in-the-u-s-%ef%bf%bc/feed/ 0 33 https://www.artismediclimited.com/2022/04/28/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan%ef%bf%bc/ https://www.artismediclimited.com/2022/04/28/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan%ef%bf%bc/#respond Thu, 28 Apr 2022 04:30:39 +0000 https://www.artismediclimited.com/?p=30 Tokyo, Japan, and Lugano, Switzerland March 28, 2022 – Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) and AMPL Group (hereinafter “Helsinn”), announced today that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK₁ receptor antagonist antiemetic drug “Arokaris^® I.V. Infusion 235mg” (generic name: fosnetupitant chloride hydrochloride) for gastrointestinal symptoms (nausea and vomiting, including delayed phase) associated with cancer chemotherapy (cisplatin, etc.).

]]> https://www.artismediclimited.com/2022/04/28/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan%ef%bf%bc/feed/ 0 30 https://www.artismediclimited.com/2022/04/26/hello-world/ https://www.artismediclimited.com/2022/04/26/hello-world/#comments Tue, 26 Apr 2022 05:24:07 +0000 https://www.artismediclimited.com/?p=1 Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

]]> https://www.artismediclimited.com/2022/04/26/hello-world/feed/ 1 1